Updated Jul 16, 2026
Eckhardt Sue Gail has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $661K.
Sue Gail Eckhardt is a director at Exelixis, Inc., a biotechnology company focused on developing and commercializing innovative cancer therapies. Her role involves overseeing the company's strategic direction and governance.
| Role | Director |
|---|---|
| Notability | 10/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-03 | EXEL | EXELIXIS, INC. | S — Open-market sale | 9.8K | $50.14 | $492K |
| 2026-05-29 | EXEL | EXELIXIS, INC. | A — Grant or award | 8.4K | $0.00 | |
| 2026-02-19 | EXEL | EXELIXIS, INC. | S — Open-market sale [10b5-1] | 3.9K | $43.79 | $169K |
Sue Gail Eckhardt is a director at Exelixis, Inc., a biotechnology company focused on developing and commercializing innovative cancer therapies. Her role involves overseeing the company's strategic direction and governance.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($661K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Eckhardt Sue Gail profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.